New HIV injection shows promise in early safety trial
NCT ID NCT05349968
First seen May 14, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This early-stage study tested a new injectable drug, Lipovirtide, in 24 adults with HIV who were not taking any other HIV medications. The main goal was to check if the drug is safe and tolerable. Researchers also looked at how the drug works in the body and whether it can lower the amount of HIV in the blood. This is a first step to see if Lipovirtide could be a future treatment option for HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing You'an Hospital, Beijing Medical University
Beijing, China
Conditions
Explore the condition pages connected to this study.